Fulgent Genetics, Inc. - Common Stock (FLGT)

A tax refund and bad debt recovery shaped results and lifted the outlook.

Fulgent Genetics (NASDAQ:FLGT) reported third-quarter revenue of $90.4 million, up 8% from a year earlier, as contributions from Bako Diagnostics and StrataDx and improving collections helped lift results. The company reaffirmed its full-year revenue forecast and narrowed its projected loss. The la

Fulgent Genetics, Joby Aviation, and Veritone pursue unconventional business models in genomics, eVTOL aircraft, and AI media, backed by notable financial and operational milestones.

Billing delays pressured margins, though acquisitions drove anatomic pathology growth.

Fulgent Genetics (NASDAQ:FLGT) reported second-quarter 2026 revenue of $85.4 million, up 20% sequentially and 4% from a year earlier, as the company incorporated a full quarter of contributions from Bako Diagnostics and StrataDx. Management also lowered its full-year revenue outlook, citing lower co

Fulgent (FLGT) Q1 2026 Earnings Transcript

Fulgent Genetics (FLGT) Earnings Transcript

Fulgent Genetics (FLGT) Earnings Call Transcript

Fulgent Genetics Q3 2025 earnings beat expectations with a surprise profit, causing a 4% pre-market stock surge. The company also raised its full-year guidance.

Fulgent Genetics has seen its fortunes shift since the pandemic. Is it a solid investment or a risky bet? Join us as we break down its performance and management decisions.

The next-generation diagnostics specialist had a beat-and-raise second quarter.

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.